Blujepa (gepotidacin) FDA approval was granted on March 25, 2025, to GSK GlaxoSmithKline. Its launch date is expected to be the second half of 2025. What Is The Use Of Blujepa? Blujepa (Gepotidacin) is a…
In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved AQNEURSA™ (levacetylleucine), the first stand-alone therapy for treating neurological symptoms of Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. Developed by IntraBio…
In the world of rare disease therapeutics, Vimseltinib has emerged as a groundbreaking oral kinase inhibitor. This innovative medication is specifically designed for adults with symptomatic tenosynovial giant cell tumor (TGCT) – a rare, non-cancerous but often debilitating condition…
In January 2025, the FDA approved Grafapex™ (treosulfan) in combination with fludarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT). This approval applies to adult and pediatric patients aged one year and…
Gomekli™ (mirdametinib) has emerged as a significant advancement in the treatment of neurofibromatosis type 1 (NF1) with symptomatic plexiform neurofibromas (PN), offering new hope to patients aged 2 years and older. 🧬 Understanding Neurofibromatosis Type…
The Alyftrek drug, a groundbreaking once-daily triple-combination therapy, received U.S. Food and Drug Administration (FDA) approval in December 2024 for the treatment of cystic fibrosis (CF) in patients aged six and older. This approval represents a…
Based on the TROPION-Breast01 trial, Daiichi Sankyo and AstraZeneca’s DATROWAY was approved for the first time in the European Union. The trial showed a 37% reduction in the risk of disease progression or death compared…
Epilepsy is a chronic neurological disorder that affects an estimated 65 million people worldwide. Briviact (brivaracetam) is a medication commonly used to treat seizures; understanding how it works and what to expect is crucial for…
Akynzeo capsule is an FDA-approved antiemetic medication specifically designed to address both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV). As chemotherapy remains a cornerstone of cancer treatment, its debilitating side effects –…
NEW YORK, April 8, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc.(TGTX) announced today that it will publish data on BRIUMVI® (ublituximab-xiiy) for the treatment of patients with relapsing multiple sclerosis (RMS). Michael S. Weiss, Chief…
In September 2024, the U.S. Food and Drug Administration (FDA) approved Cobenfy (xanomeline and trospium chloride), marking the first new class of schizophrenia treatment in over three decades. Developed by Karuna Therapeutics and acquired by…
Major depressive disorder (MDD) has been ranked as the third cause of the burden of disease worldwide in 2008 by WHO, which has projected that this disease will rank first by 2030. If you are…
